Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function - PubMed
4 hours ago
- #JAK inhibitors
- #metabolic reprogramming
- #CD8 T cells
- JAK inhibitors (JAKis) used for autoimmune diseases increase infection risk by impairing CD8 T cell function.
- In vitro studies show JAKis disrupt metabolic reprogramming in CD8 T cells, reducing glycolysis and glucose uptake even when activation markers are upregulated.
- JAKi-treated CD8 T cells exhibit decreased cytokine production, cytotoxic molecules, and mTOR activity, with increased p53-associated stress signaling.
- Memory CD8 T cells from JAKi-treated rheumatoid arthritis patients show similar metabolic and signaling alterations, confirming clinical relevance.
- These findings link JAKi-induced metabolic disruption in CD8 T cells to impaired effector function and heightened infection susceptibility in patients.